Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation

Maximilian Merz; Lina Jansen; Felipe A. Castro; Jens Hillengass; Hans Salwender; Katja Weisel; Christof Scheid; Sabine Luttmann; Katharina Emrich; Bernd Holleczek; Alexander Katalinic; Alice Nennecke; Christian Straka; Christian Langer; Monika Engelhardt; Hermann Einsele; Nicolaus Kröger; Dietrich Beelen; Peter Dreger; Hermann Brenner; Hartmut Goldschmidt

doi:10.1016/j.ejca.2016.04.004

Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation

Maximilian Merz^*, Lina Jansen, Felipe A. Castro, Jens Hillengass, Hans Salwender, Katja Weisel, Christof Scheid, Sabine Luttmann, Katharina Emrich, Bernd Holleczek, Alexander Katalinic, Alice Nennecke, Christian Straka, Christian Langer, Monika Engelhardt, Hermann Einsele, Nicolaus Kröger, Dietrich Beelen, Peter Dreger, Hermann BrennerHartmut Goldschmidt

^*Corresponding author for this work

Institute of Social Medicine and Epidemiology

24 Citations (Scopus)

Abstract

Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011. Conclusion We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.

Original language	English
Journal	European Journal of Cancer
Volume	62
Pages (from-to)	1-8
Number of pages	8
ISSN	0959-8049
DOIs	https://doi.org/10.1016/j.ejca.2016.04.004
Publication status	Published - 01.07.2016

Funding

This work was supported partly by the German Cancer Aid (Deutsche Krebshilfe) (grant numbers 108257 and 110446 ). The authors thank Franziska Strehle from the Deutsche Register für Stammzelltransplantation (DRST) for providing the data and administrative support. Members of the GEKID Cancer Survival Working Group: Karla Geiss, Martin Meyer (Cancer Registry of Bavaria), Andrea Eberle, Sabine Luttmann (Cancer Registry of Bremen), Roland Stabenow (Cancer Registry of Berlin and the New Federal States), Stefan Hentschel, Alice Nennecke (Hamburg Cancer Registry), Joachim Kieschke, Eunice Sirri (Cancer Registry of Lower Saxony), Bernd Holleczek (Saarland Cancer Registry), Katharina Emrich (Cancer Registry of Rhineland-Palatinate), Hiltraud Kajüter, Volkmar Mattauch (Cancer Registry of North Rhine-Westphalia), Alexander Katalinic, Nora Eisemann (Cancer Registry of Schleswig-Holstein), Klaus Kraywinkel (Robert Koch Institute, Berlin), Hermann Brenner, Felipe Castro, and Lina Jansen (German Cancer Research Centre). Appendix A

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Center for Population Medicine and Public Health (ZBV)

Access to Document

10.1016/j.ejca.2016.04.004

Cite this

Merz, M., Jansen, L., Castro, F. A., Hillengass, J., Salwender, H., Weisel, K., Scheid, C., Luttmann, S., Emrich, K., Holleczek, B., Katalinic, A., Nennecke, A., Straka, C., Langer, C., Engelhardt, M., Einsele, H., Kröger, N., Beelen, D., Dreger, P., ... Goldschmidt, H. (2016). Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation. European Journal of Cancer, 62, 1-8. https://doi.org/10.1016/j.ejca.2016.04.004

@article{0774c8d799ba4eaeb3090b746584983f,

title = "Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation",

abstract = "Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0\%; 65-69 years: 6.6-23.7\%; 70-79 years: 0.4-4.0\%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2\% versus 66.1\%; 65-69: 57.4\% versus 61.7\%; 70-79: 51.0\% versus 56.6\%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5\%) and for patients treated with ASCT (+11.8\%). Differences in RS between these groups increased over time from +1.9\% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2\% higher survival in 2009-2011. Conclusion We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.",

author = "Maximilian Merz and Lina Jansen and Castro, \{Felipe A.\} and Jens Hillengass and Hans Salwender and Katja Weisel and Christof Scheid and Sabine Luttmann and Katharina Emrich and Bernd Holleczek and Alexander Katalinic and Alice Nennecke and Christian Straka and Christian Langer and Monika Engelhardt and Hermann Einsele and Nicolaus Kr{\"o}ger and Dietrich Beelen and Peter Dreger and Hermann Brenner and Hartmut Goldschmidt",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.ejca.2016.04.004",

language = "English",

volume = "62",

pages = "1--8",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

Merz, M, Jansen, L, Castro, FA, Hillengass, J, Salwender, H, Weisel, K, Scheid, C, Luttmann, S, Emrich, K, Holleczek, B, Katalinic, A, Nennecke, A, Straka, C, Langer, C, Engelhardt, M, Einsele, H, Kröger, N, Beelen, D, Dreger, P, Brenner, H & Goldschmidt, H 2016, 'Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation', European Journal of Cancer, vol. 62, pp. 1-8. https://doi.org/10.1016/j.ejca.2016.04.004

TY - JOUR

T1 - Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation

AU - Merz, Maximilian

AU - Jansen, Lina

AU - Castro, Felipe A.

AU - Hillengass, Jens

AU - Salwender, Hans

AU - Weisel, Katja

AU - Scheid, Christof

AU - Luttmann, Sabine

AU - Emrich, Katharina

AU - Holleczek, Bernd

AU - Katalinic, Alexander

AU - Nennecke, Alice

AU - Straka, Christian

AU - Langer, Christian

AU - Engelhardt, Monika

AU - Einsele, Hermann

AU - Kröger, Nicolaus

AU - Beelen, Dietrich

AU - Dreger, Peter

AU - Brenner, Hermann

AU - Goldschmidt, Hartmut

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011. Conclusion We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.

AB - Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011. Conclusion We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.

UR - https://www.scopus.com/pages/publications/84966394751

U2 - 10.1016/j.ejca.2016.04.004

DO - 10.1016/j.ejca.2016.04.004

M3 - Journal articles

C2 - 27185572

AN - SCOPUS:84966394751

SN - 0959-8049

VL - 62

SP - 1

EP - 8

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this